Wilk: How Much Runway Did the 2025 Raises and 2026 Rights Issue Really Buy
Wilk's two 2025 equity raises brought in ILS 1.547 million of financing cash, almost against ILS 1.745 million of operating cash burn, so they mostly funded the year rather than built a cushion for the next one. The March 2026 rights issue adds another attempt to raise about ILS 1.1 million, but with 750,000 new shares and 750,000 free warrants the price is still dilution, not a durable fix.
The main article made a clear point: Wilk managed to cut the burn, but it did not solve the bottleneck between commercialization and cash. This follow-up isolates only the funding layer. The question here is not whether the company can raise equity. The question is how much time the July 2025 placement, the December 2025 placement, and the March 2026 rights issue actually bought, and what dilution came with that time.
The short answer is blunt. The 2025 financings brought ILS 1.547 million of cash into the company, almost against ILS 1.745 million of negative operating cash flow. That means they funded the year far more than they created a real cushion for the next one. Wilk ended 2025 with ILS 1.192 million of cash, and by the report date that was already down to about ILS 552 thousand.
March 2026 does not turn that into a multi-year funding answer. The company itself says the rights issue was intended to raise about ILS 1.1 million. That matters for a company this small, but it comes together with 750,000 new shares and 750,000 free warrants. It is oxygen. It is not funding independence.
There is another point the market can easily misread. "No debt" sounds clean. In practice, as of 31 December 2025 and at the report date, the company also says it had no bank or non-bank loans and no bank credit facilities. In other words, there is no debt overhang, but there is also no credit backstop. The only safety layer is equity, rights, and warrants.
What The 2025 Raises Actually Bought
The right starting point has to be conservative, but not dramatic. In 2025 Wilk's operating cash burn fell to ILS 1.745 million, or roughly ILS 145 thousand per month. That is already far below 2024. But it is also a year flattered by unusually heavy cost cuts, and even that year benefited from ILS 314 thousand of positive investing cash flow from deposit withdrawals and asset sales. So this is a relatively generous runway base, not a harsh one.
That chart is the core of the read. If the 2025 financings had really solved the runway problem, they should still have been sitting in cash at year-end. Instead, the year closed with only ILS 116 thousand more cash than it started with. Most of the time bought had already been spent inside the year.
| Move | Cash to company | Time bought on the 2025 burn rate | Dilution cost |
|---|---|---|---|
| July 2025 private placement | ILS 0.200 million | About 1.4 months | 20,000 issued shares and 1.5 million non-traded warrants exercisable into 60,000 shares |
| December 2025 private placement | ILS 1.347 million gross | About 9.3 months gross | 1,036,152 issued shares and 1,036,152 warrants at a 130 agorot strike |
| December 2025 issue costs | ILS 0.110 million | About 0.8 months of burn removed from the cushion | Reduced the net cash value of the round |
| Cash at report date | ILS 0.552 million | Less than 4 months | No credit line to bridge a delay |
The table leads to a simple conclusion. The July raise barely changed the runway. It bought a little more than a month. December was far more meaningful, but even that round alone did not create two years of room. Together, the 2025 financings bought roughly 10.6 months of burn on the 2025 operating base. By the time the annual report was signed, most of that time had already been used.
The balance sheet supports that reading. Working capital at year-end was only ILS 280 thousand, and equity remained negative at a deficit of ILS 1.028 million. So even after two equity rounds, Wilk did not get to what looks like a stable capital cushion.
March 2026 Rights: More Time, Not A Balance-Sheet Reset
March 2026 comes exactly where the 2025 raises were already close to exhausted. The company says its main funding sources are cash on hand, warrant exercises, private placements, and public equity raising, including the March 2026 rights issue. In the same breath, it says it has no loans and no credit facilities. That means the rights issue was not an opportunistic move. It was a direct extension of the going-concern problem.
Under the disclosed terms, the company issued 10,000 rights. Each rights unit allowed the holder to buy 75 ordinary shares at ILS 1.5 per share, plus 75 Series 5 warrants for no consideration, so the total price per rights unit was ILS 112.5. Elsewhere in the same report, the company says the transaction was meant to raise about ILS 1.1 million.
Converted into months of activity, that rights issue buys roughly 7.6 months of runway on the 2025 burn rate. Add it to the ILS 552 thousand that remained at the report date, and the combined funding envelope reaches only about 11.4 months on that same base. That is meaningful for a company Wilk's size, but it still leaves the core thesis unchanged: even after the rights issue, the company is operating on something like a one-year horizon, not on a clean funding solution that disconnects it from the market.
There is also direct dilution that is easy to quantify. The issued and paid-up share count at year-end 2025 stood at 3,858,657 shares. The March 2026 rights issue alone represents up to 750,000 new shares, or about 19.4% of that base, even before one free warrant is exercised.
That chart matters because it shows that the rights issue is not just a cash move. It is another layer in an equity chain that also creates overhang. December 2025 already added 1,036,152 warrants, which alone equal about 26.9% of the year-end 2025 share base. July adds a smaller layer, and the rights issue itself adds both shares and free warrants.
The Warrant Stack Is Emergency Liquidity Only If The Stock Cooperates
This may be the most important detail in the whole continuation. Warrants can easily be framed as if they were an almost automatic future funding source. They are not. They become cash only if the share price allows it and if holders choose to exercise.
As of 3 April 2026, the stock traded at 179.8 agorot, on daily turnover of only ILS 12,246 and at a market cap of about ILS 8.2 million. That snapshot says two things at once. First, the market price was above both the March 2026 rights price of 150 agorot per share and the December 2025 warrant strike of 130 agorot. So the equity window was still open. Second, this remains a very thinly traded stock, which means any meaningful warrant exercise comes with a very visible equity impact.
If all of the December 2025 warrants were exercised, the company could receive roughly another ILS 1.347 million, almost exactly the size of the original round, but only by issuing another 1,036,152 shares. That is real potential cash. It is also real dilution. The right way to read these warrants is therefore as emergency liquidity that depends on the stock price, not as a clean source of capital.
In share terms, the open layers highlighted by the July 2025, December 2025, and March 2026 documents add up to 1,846,152 potential shares through warrants alone. That equals about 47.8% of the year-end 2025 share base. Add the 750,000 shares from the rights issue itself, and the funding map becomes clear: almost every major future financing lever still runs through a wider equity base.
That is also why "no debt" is not automatically good news here. In another company, no debt could mean balance-sheet freedom. Here it mostly means there is no alternative funding layer if the stock price weakens or commercialization slips again.
Deferred Revenue Is Not Extra Runway
One more point can mislead readers, and it sits on the liability side of the balance sheet. Wilk carries ILS 1.624 million of non-current deferred revenue. On a superficial read, that can look like money that already came in and somehow eases the 2026 funding picture. That is not the right reading.
That cash was received back in 2021 under the agreement with the Central Bottling Company, and it is still presented as deferred revenue because the company identified two main performance obligations: a license to use the technology after successful completion of development, and a right to purchase components at a discounted price. As of 31 December 2025, the conditions for revenue recognition still had not been met, so no revenue had been recognized under that agreement.
The economic meaning is two-sided. First, this is not fresh cash for 2026. The cash arrived years ago. Second, it is not hidden earnings that can be treated as balance-sheet reinforcement. Until development is completed and products are actually sold, the amount stays on the balance sheet as a liability. That is exactly why the year-end 2025 balance sheet shows ILS 1.192 million of cash on one side, but ILS 1.624 million of deferred revenue and a negative equity balance on the other.
That detail matters especially in Wilk's case because it sharpens the difference between money received in the past and runway available now. This liability is larger than the year-end cash balance. It cannot be treated as another safety layer in the going-concern debate.
Bottom Line
The 2025 raises and the 2026 rights issue bought Wilk time, but less time than a financing headline might suggest. July 2025 bought a little more than one month. December 2025 bought roughly nine months of gross burn. By the report date, most of that time had already been consumed, so March 2026 came back to the same place: another attempt to buy less than a year of air, this time through rights.
The message to shareholders is straightforward. Wilk did not build a clean funding bridge in 2025. It built a chain of short equity layers, each of which buys more time but also widens the share base again. Until commercialization moves from promise to revenue, that remains the core equation.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.